Icatibant

What is Icatibant?

Icatibant (brand name FIRAZYR, development code HOE 140) is a synthetic decapeptide selective antagonist of the bradykinin B2 receptor. It was approved by the FDA on August 25, 2011 for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.

Icatibant is self-administered as a subcutaneous injection at the onset of an HAE attack and can be used at home, providing patients with on-demand control of attacks without requiring emergency department visits or IV therapy.

Background — Hereditary Angioedema

HAE is a rare genetic disorder caused by deficiency or dysfunction of C1 esterase inhibitor (C1-INH). C1-INH normally regulates the kallikrein-kinin pathway; without it, episodic uncontrolled cleavage of high-molecular-weight kininogen by plasma kallikrein produces bradykinin, which causes vascular leak and the characteristic painful, non-pruritic, non-allergic edema of skin, gut, and (most dangerously) airway.

Bradykinin is the proximate cause of HAE attack symptoms. Targeting bradykinin or its receptor pharmacologically aborts attacks.

Structure and Mechanism

Icatibant's design started from native bradykinin and inverted its pharmacology. Multiple D-amino acids and unnatural residues:

• Block the receptor without activating it
• Confer enzymatic stability (resistance to ACE, neutral endopeptidase, and other peptidases that normally degrade bradykinin)
• Selective for the B2 receptor (the bradykinin receptor implicated in vasodilation, increased permeability, and HAE attacks)

Pharmacological effects:

• Selective B2 receptor antagonism — blocks bradykinin signaling at the level of vascular endothelium
• Reverses vascular leak and inflammation of acute HAE attacks
• Half-life ~1.4 hours with fast onset of symptom relief

Clinical Evidence

FAST-3 Phase 3 (NEJM 2011):

• 88 HAE patients during acute attacks, randomized to icatibant 30 mg SC or placebo
• Median time to ≥50% reduction in symptom severity: 2.0 hours vs 19.8 hours placebo (p<0.001)
• Significant improvements in visual analog scale of attack severity
• Tolerated well; transient injection-site swelling was the most common adverse event

Earlier FAST-1 and FAST-2 trials in 2009-2010 also demonstrated efficacy.

Approval History

• August 25, 2011 — FDA approval for acute HAE attacks in adults
• August 2008 — EMA approval (predates FDA)
• Multiple generic icatibant approvals 2019-2024

Place in Therapy

Icatibant is one of three approved on-demand therapies for HAE attacks:

• Icatibant (Firazyr) — bradykinin B2 antagonist, SC self-administered
• Plasma-derived C1-INH (Berinert) or recombinant C1-INH (Ruconest) — IV protein replacement
• Ecallantide (Kalbitor) — kallikrein inhibitor, SC physician-administered

For self-administration at home, icatibant is the patient-preferred option for many patients because:

• Single ready-to-use prefilled syringe
• No reconstitution needed
• 30 mg fixed dose
• Outpatient self-injection

For prophylaxis (rather than acute attacks), other agents are used: long-term prophylaxis with C1-INH replacement, lanadelumab, or berotralstat.

Safety Profile

Most common adverse events:

• Injection-site reactions — erythema, swelling, warmth, pruritus, pain (~98% of injections, but typically mild and self-limited)
• Headache, dizziness, fever, nausea
• Pyrexia, transaminase elevations

Notably, icatibant does not produce the bleeding risk of plasma-derived C1-INH or the antibody hypersensitivity risk seen with ecallantide.

Distinction from Other HAE Therapies

Icatibant's 2011 approval was a significant advance in HAE care — providing patients with self-administered on-demand control of unpredictable, sometimes life-threatening attacks.